ASCO Meeting 2024 Participation

2024 Young Investigator Award Recipients

Rebecca Forman, MD
Yiduo Hu, MD, PhD
Tendai Kwaramba, MD, MSc

ASCO Education Scholar

Thejal Srikumar, MD

Friday, May 31

Workshop
In-Person Workshop: Genomics 101 for Oncologists
Medical Oncologist Perspective
May 31; 1:00 – 5:00 PM CDT
Presenter: Michael E. Hurwitz, MD, PhD
Location: S105ab

Saturday, June 1

Oral Abstract
Genitourinary Cancer—Kidney and Bladder
Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).
June 1; 8:42 – 8:48AM CDT
Presenter: Soki Kashima
Location: S100bc | Abstract 4515

Poster Session
Developmental Therapeutics—Immunotherapy
SH2B3 mutation as a potential resistance mechanism to oncolytic virus therapy.
June 1; 9:00 – 12:00PM CDT
Presenter: Philippos Costa
Location: Hall A | Abstract 2578 | Poster Bd 57

Poster Session
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Comprehensive characterization of ERBB2 genomic alterations in lung cancer.
Poster Session
Sarcoma

**Sorafenib treatment duration in desmoid tumors.**
June 1; 1:30 – 4:30PM CDT
Presenter: Philippos Costa
Location: Hall A | Abstract 11585 | Poster Bd 511

Poster Session
Central Nervous System Tumors

**Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.**
Presenter: Nicholas Blondin
June 1; 9:00 – 12:00PM CDT
Location: Hall A | Abstract: 2029 | Poster Bd 328

Poster Session
Developmental Therapeutics—Immunotherapy

**Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.**
June 1; 9:00 – 12:00PM CDT
Presenter: Alexander Frey
Location: Hall A | Abstract 2637 | Poster Bd 116

Poster Session
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.**
June 1; 9:00 – 12:00PM CDT
Senior Author: Barbara Burtness
Location: Hall A | Abstract TPS2701 | Poster Bd 164a

Poster Session
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer.**
June 1; 9:00 – 12:00 PM CDT
Senior Author: Patricia LoRusso
Location: Hall A | Abstract TPS3183 | Poster Bd 316a

Poster Session
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**Comprehensive characterization of ERBB2 genomic alterations in lung cancer.**
June 1; 9:00 – 12:00PM CDT
Presenter: Talal El Zarif
Location: Hall A | Abstract 3148 | Poster Bd 293
**Poster Session**

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.**

June 1; 9:00 – 12:00PM CDT
Presenter: Aarti Bhatia
Location: Hall A | Abstract TPS3164 | Poster Bd 307a

**Education Session**

Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates

**Role of Payload and Antibody in Predicting Resistance to Antibody-Drug Conjugates**

June 1; 1:15 – 2:30PM CDT
Presenter: Patricia LoRusso
Location: Hall D1

**Education Session**

Tackling the Tough Stuff: Managing Challenging Symptoms and Patient Conversations Around Goals of Care

**Primary Palliative Care Skills: How to Integrate Into Your Oncology Practice**

June 1; 1:15 – 1:30PM CDT
Presenter: Jennifer Kapo
Location: E450a

**Education Session**

State-of-the-Art Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma: Current Advances and Future Frontiers

**Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches**

June 1; 1:30 – 1:45 PM CDT
Presenter: David Braun
Location: Hall D2

**Poster Session**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).**

June 1; 1:30 – 4:30PM CDT
Presenter: Jacquelyne Gaddy
Location: Hall A | Abstract 4138 | Poster Bd 118

**Poster Session**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.**

June 1; 1:30 – 4:30PM CDT
Presenter: Pamela Kunz
**Poster Session**

Melanoma/Skin Cancers

**Correlation of eTILs with recurrence free survival (RFS) in stage IIB-III A melanoma and use as biomarker for stratification for clinical trials.**

June 1; 1:30 – 4:30PM CDT  
Presenter: Thazin Aung  
Location: Hall A | Abstract 9567 | Poster Bd 351

**Education Session**

Advanced Lung Cancer: State-of-the-Art Approaches and Insights

**Small Cell Lung Cancer**

June 1; 3:00 – 3:15 PM CDT  
Presenter: Anne C. Chiang  
Location: S406

**Oral Abstract**

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2– breast cancer.**

June 1; 4:24 – 4:36PM CDT  
Presenter: Pat LoRusso  
Location: Hall D1 | Abstract 3006 |

**Education Session**

Navigating the Complexities of Brain Metastases Management

June 1; 4:45 -6:00 PM CDT  
Chair: Sarah B. Goldberg, MD  
Location: E450a

**Education Session**

Has the Revolution in Precision Medicine Reached Patients With Brain Metastases?

June 1; 4:45 -5:00 PM CDT  
Presenter: Sarah B. Goldberg, MD  
Location: E45a

---

**Sunday, June 2**

**Oral Abstract**

Gastrointestinal Cancer—Colorectal and Anal
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
June 2; 10:24 – 10:36 AM CDT
Senior Author: Michael Cecchini
Location: Arie Crown Theater | Abstract 3508

Poster Session
Genitourinary Cancer—Kidney and Bladder
Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).
June 2; 9:00 – 12:00PM CDT
Senior Author: David Braun
Location: Hall A | Abstract 4546 | Poster Bd 241

Poster Session
Genitourinary Cancer—Kidney and Bladder
A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.
June 2; 9:00 – 12:00PM CDT
Senior Author: Dan Petrylak
Location: Hall A | Abstract TPS4619 | Poster Bd 308a

Poster Session
Breast Cancer—Local/Regional/Adjuvant
Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer.
article
June 2; 9:00 – 12:00PM CDT
Presenter: Daniel O'Neil
Location: Hall A | Abstract 522 | Poster Bd 114

Poster Session
Breast Cancer
Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.
June 2; 9:00 – 12:00PM CDT
Senior Author: Maryam Lustberg
Location: Hall A | Abstract 1065 | Poster Bd 43

Poster Session
Head and Neck Cancer
Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study.
June 2; 9:00 – 12:00 PM CDT
Senior Author: Joseph Kim
Location: Hall A | Abstract 6079 | Poster Bd 395
Breast Cancer

Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
June 2; 9:00 – 12:00PM CDT
Presenters: Nicole Odzer
Location: Hall A | Abstract 1104 | Poster Bd 82

Poster Session
Breast Cancer—Metastatic
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).
June 2; 9:00 – 12:00PM CDT
Presenter: Melissa Taylor
Location: Hall A | Abstract 1092 | Poster Bd 70

Poster Session
Breast Cancer—Local/Regional/Adjuvant
Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.
June 2; 9:00 – 12:00PM CDT
Presenter: Alejandro Rios-Hoyo
Location: Hall A | Abstract 573 | Poster Bd 165

Case-Based Panel
Optimizing Treatment of Locally Advanced Non−Small Cell Lung Cancer: A Multimodal Approach in the Immunotherapy Era
Radiation Oncologist Perspective
June 2; 11:30 AM CDT
Presenter: Henry Soo-Min Park
Location: Hall D1

Clinical Science Symposium
Care Delivery and Quality Care
Navigating Global Cancer Care: Conflict, Access, and Delivery
June 2; 12:18 – 12:30 PM CDT
Presenter: Daniel O’Neil
Location: S100bc

Oral Abstract
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
June 2; 4:30 – 6:00PM CDT
Presenter: Ritujith Jayakrishnan
Location: S406 | Abstract 8013

Monday, June 3
Oral Abstract
Genitourinary Cancer—Kidney and Bladder
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
June 3; 8:24 – 8:36AM CDT
Presenter: Daniel Petrylak
Location: Hall B1 | Abstract 4503

Poster Session
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naïve patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.
June 3; 9:00 – 12:00PM CDT
Presenter: Amer Zeidan
Location: Hall A | Abstract 6565 | Poster Bd 124

Poster Session
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.
June 3; 9:00 – 12:00PM CDT
Presenter: Amer Zeidan
Location: Hall H | Abstract 6566 | Poster Bd 125

Poster Session
Hematologic Malignancies—Plasma Cell Dyscrasia
Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
June 3; 9:00 – 12:00PM CDT
Presenter: Poy Theprungsirikul
Location: Hall A | Abstract 7549 | Poster Bd 186

Poster Session
Quality Care/Health Services Research
Oral cancer drug repositories: Challenges and solutions.
June 3; 9:00 – 12:00PM CDT
Senior Author: Osama Abdelghany
Location: Hall A | Abstract 11063 | Poster Bd 258

Poster Session
Quality Care/Health Services Research
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.
June 3; 9:00 – 12:00PM CDT
Presenter: Laura Baum
Poster Session
Quality Care/Health Services Research
Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
June 3; 9:00 – 12:00PM CDT
Senior Author: Maureen Can
Location: Hall A | Abstract 11092 | Poster Bd 287

Poster Session
Hematologic Malignancies—Plasma Cell Dyscrasia
Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.
June 3; 9:00 – 12:00PM CDT
Presenter: Sabrina Browning
Location: Hall A | Abstract 7559 | Poster Bd 196

Oral Abstract
Medical Education and Professional Development
Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.
Presenter: Thejal Srikumar
June 3; 9:51 – 9:57AM CDT
Location: E450a | Abstract 9004

Oral Abstract
Genitourinary Cancer—Prostate, Testicular, and Penile
ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.
June 3; 1:27 – 1:33PM CDT
Presenter: Daniel Petrylak
Location: Hall B1 | Abstract 5011

Poster Session
Symptom Science and Palliative Care
Factors associated with sexual function and sexual satisfaction in young women with breast cancer.
June 3; 1:30 – 4:30PM CDT
Presenter: Ana Ferrigno Guajardo
Location: Abstract 12062 | Poster Bd 191

Poster Session
Lung Cancer
Updated results from COAST, a phase 2 study of durvalumab (D) + oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).
June 3; 1:30 – 4:30PM CDT
Senior Author: Roy Herbst
Location: Hall A | Abstract 8046 | Poster Bd 308
**Poster Session**
Prevention, Risk Reduction, and Genetics

June 3; 1:30 – 4:30PM CDT
Presenter: Louise Wang
Location: Hall A | Abstract 10544 | Poster Bd 71

**Poster Session**
Lung Cancer

*Lymph node metastasis prediction with non-small cell lung cancer histopathology imaging.*
Presenter: Victor Lee
June 3; 1:30 – 4:30PM CDT
Location: Hall A | Abstract 8063 | Poster Bd 325

**Poster Session**
Prevention, Risk Reduction, and Genetics

*Associations between violence, distress, and cancer in transgender and non-transgender people.*
June 3; 1:30 – 4:30PM CDT
Presenter: Ash Alpert
Location: Abstract 10566 | Poster Bd 93

**Poster Session**
Prevention, Risk Reduction, and Genetics

*Population attributable fraction of reproductive factors in triple negative breast cancer by race.*
June 3; 1:30 – 4:30PM CDT
Presenter: Rachel Jaber Chehayeb
Location: Hall A | Abstract 10522 | Poster Bd 49

**Poster Session**
Symptom Science and Palliative Care

*Neurofilament light chains: A biomarker for vincristine-related neuropathy.*
June 3; 1:30 – 4:30PM CDT
Senior Author: Maryam Lustberg
Location: Hall A | Abstract 12114 | Poster Bd 243

**Poster Session**
Prevention, Risk Reduction, and Genetics

*Blood type as a risk factor for pancreatic ductal adenocarcinoma.*
June 3; 1:30 – 4:30PM CDT
Presenter: Navid Rahimi Larki
Location: Hall A | Abstract 10559 | Poster Bd 86

**Poster Session**
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

*Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.*
June 3; 1:30 – 4:30PM CDT
Presenter: Amin Nassar
Poster Session
Lung Cancer—Non-Small Cell Metastatic
Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.
June 3; 1:30 – 4:30PM CDT
Presenter: Kelsey Matteson
Location: Hall A | Abstract 8106 | Poster Bd 368

Clinical Science Symposium
Making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer
June 3; 3:12 – 3:24 PM CDT
Presenter: Barbara Burtness
Location: E451 | Abstract 8602 | Poster Bd 466

Education Session
Shaping the Future of Cancer Care: Diverse Perspectives on Emerging Health Policies
Impact of Emerging Legislation on Cancer Care—A Hospital-Based Perspective
June 3; 3:15 – 3:30 PM CDT
Presenter: Osama Abdelghany
Location: S102

Oral Abstract
Breast Cancer—Local/Regional/Adjuvant
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
June 3; 5:24 – 5:36 PM CDT
Presenter: Lajos Pusztai
Location: Hall B1 | Abstract 508

Tuesday, June 4

Oral Abstract Session
Head and Neck Cancer
Chair: Aarti K. Bhatia
June 4; 9:45 – 12:45 PM CDT
Location: S100a | Live Stream

Oral Abstract
Head and Neck Cancer
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).
Central Nervous System Tumors

**HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer.**
Senior Author: Kurt Schalper
Location: Abstract e14014

Care Delivery/Models of Care

**Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.**
Senior Author: Neal Fischbach
Location: Abstract e13586

Pediatric Oncology

**Modeling response to alkylating chemotherapy in a syngeneic model of MMR-deficient glioma.**
Senior Author: Deepti Bhatt
Location: Abstract e22001
[https://meetings.asco.org/abstracts-presentations/231055](https://meetings.asco.org/abstracts-presentations/231055)

Breast Cancer

**Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer.**
Senior Author: Maryam Lustberg
Location: Abstract #e12639

Sarcoma

**Survival trends of soft tissue sarcomas and gastrointestinal stromal tumors from 1995 to 2019: A SEER database analysis.**
Senior Author: Philippos Costa
Location: Abstract #e23528

Melanoma/Skin Cancers

**Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.**
Author: Daniel Lee
Location: Abstract e21522
Publication Only
Symptom Science and Palliative Care
Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.
Author: Neal Fischbach
Location: Abstract e24140

Publication Only
Care Delivery and Quality Care
Personalized risk assessment of new onset depression in long-term cancer survivors.
article
Author: Melissa Taylor
Location: Abstract e13798

Publication Only
Medical Education and Professional Development
A medical school curriculum to foster the physician-patient relationship through narrative medicine.
article
Author: Johnathan Yao
Location: Abstract e21015

Publication Only
Care Delivery/Models of Care
The unmet needs of women with metastatic breast cancer in Mexico: A qualitative study.
Author: Ana Ferrigno Guajardo
Location: Abstract e13547

Publication Only
Lung Cancer
Real world outcomes of patients with small cell lung cancer (SCLC) presenting with brain metastasis at diagnosis in a single institution health system.
Author: Julia Joseph
Location: Abstract: e20136